Wall Street analysts expect Sangamo Therapeutics Inc (NASDAQ:SGMO) to announce $74.50 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Sangamo Therapeutics’ earnings. The lowest sales estimate is $15.50 million and the highest is $183.00 million. Sangamo Therapeutics reported sales of $17.55 million in the same quarter last year, which indicates a positive year-over-year growth rate of 324.5%. The business is expected to announce its next earnings report on Wednesday, August 5th.
On average, analysts expect that Sangamo Therapeutics will report full year sales of $157.20 million for the current financial year, with estimates ranging from $59.70 million to $300.60 million. For the next fiscal year, analysts expect that the company will report sales of $117.58 million, with estimates ranging from $62.10 million to $156.15 million. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Sangamo Therapeutics.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.14). Sangamo Therapeutics had a negative net margin of 89.31% and a negative return on equity of 22.68%. The business had revenue of $13.10 million for the quarter, compared to analyst estimates of $22.73 million. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. The business’s revenue was up 61.7% on a year-over-year basis.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC purchased a new stake in Sangamo Therapeutics in the 4th quarter worth $824,000. Goldman Sachs Group Inc. boosted its stake in Sangamo Therapeutics by 1.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,286,595 shares of the biopharmaceutical company’s stock worth $10,769,000 after purchasing an additional 22,062 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Sangamo Therapeutics during the 1st quarter worth $1,069,000. Panagora Asset Management Inc. acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $1,406,000. Finally, Amia Capital LLP acquired a new stake in Sangamo Therapeutics during the 4th quarter worth $311,000. 52.92% of the stock is owned by institutional investors.
Shares of NASDAQ:SGMO traded up $0.04 during trading on Thursday, hitting $8.77. 1,634,000 shares of the stock traded hands, compared to its average volume of 2,356,573. The company has a quick ratio of 5.98, a current ratio of 5.98 and a debt-to-equity ratio of 0.10. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -10.57 and a beta of 2.25. The company has a fifty day moving average price of $10.47 and a two-hundred day moving average price of $8.39. Sangamo Therapeutics has a 52-week low of $4.81 and a 52-week high of $13.33.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.